KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $941000.0.

  • Bionano Genomics' Share-based Compensation fell 5726.61% to $941000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 5037.59%. This contributed to the annual value of $9.7 million for FY2024, which is 3585.45% down from last year.
  • Bionano Genomics' Share-based Compensation amounted to $941000.0 in Q3 2025, which was down 5726.61% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Share-based Compensation ranged from a high of $6.1 million in Q3 2022 and a low of $371000.0 during Q1 2021
  • Moreover, its 5-year median value for Share-based Compensation was $3.0 million (2024), whereas its average is $3.2 million.
  • In the last 5 years, Bionano Genomics' Share-based Compensation surged by 127520.22% in 2022 and then crashed by 5818.82% in 2025.
  • Bionano Genomics' Share-based Compensation (Quarter) stood at $4.8 million in 2021, then grew by 14.1% to $5.5 million in 2022, then crashed by 38.46% to $3.4 million in 2023, then tumbled by 42.59% to $1.9 million in 2024, then tumbled by 51.39% to $941000.0 in 2025.
  • Its Share-based Compensation stands at $941000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $1.6 million for Q1 2025.